Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
SAT-3247 Phase 2 Results Expected
SAT-3247 • Duchenne Muscular Dystrophy
Target Indication
Duchenne Muscular Dystrophy
Clinical Trial
Last updated: 12/18/2025
MSCLF
Satellos Bioscience Inc.